Lupkynis
(Voclosporin)ApprovedSmall molecule
Aurinia PharmaceuticalsVoclosporin is used to treat lupus nephritis, which is kidney damage caused by lupus (an autoimmune disease). It helps reduce inflammation in the kidneys and can improve kidney function in patients with this condition.[2] Lupkynis is currently approved and in use across 9 indications[4].[1]
Lupkynis is one of 175 small molecule programs targeting Panuveitis. It is currently in Approved.
9
Indications
23
Total Trials
4
Active Trials
174
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
105 competitors in Kidney Disease
#DrugCompanyPhaseTrials
1Lupkynis
Aurinia PharmaceuticalsApproved
Vimpat
UCBApproved
Elunate
TakedaApproved
Aubagio
SanofiApproved
Lorbrena
PfizerApproved
Leqvio
NovartisApproved
Uloric
TakedaApproved
Vistide
GileadApproved
Cibinqo
PfizerApproved
Scemblix
NovartisApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lupus Nephritis5 trials
Show 2 more trials
Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With Prednisolone, Mycofenolate Mofetil and Voclosporin as Compared to Mycofenolate Mofetil and Prednisolone, an Open Label Randomized Controlled Trial
Recruiting·AAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)·Approved·NCT07760480·55 enrolled
Lupus3 trials
Kidney Transplant2 trials
Safety and Efficacy2 trials
7 more indications
Interaction1 trial
Keratoconjunctivitis sicca1 trial
Eye Disease1 trial
Focal Segmental Glomerulosclerosis1 trial
Treatment1 trial
Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus
Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05306873·12 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 22, 2021
LUPKYNIS
NDA NDA213716
Jan 22, 2021
LUPKYNIS
NDA NDA213716
Apr 29, 2024
LUPKYNIS
NDA NDA213716
Oct 8, 2025
LUPKYNIS
NDA NDA213716
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lupkynis drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Voclosporin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
- [8]